Processa Pharmaceuticals (PCSA) CEO adds 1,843 shares in open-market buy

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock in the open market. He purchased 1,843 shares of common stock at $2.97 per share, bringing his directly held position to 5,492 shares. The filing also lists indirect holdings of 3,488 shares held under "George Ng IRRA FOB George Ng" and 800 shares held through the "Ng Cha Family Trust," showing both personal and related-entity ownership of Processa common stock.

Insider Trade Summary

Net Buyer: 1,843 shares ($5,474)

Net Buy 3 txns

Insider Ng George K

Role Chief Executive Officer

Bought 1,843 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,843	$2.97	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,492 shares (Direct); Common Stock — 3,488 shares (Indirect, George Ng IRRA FOB George Ng)

Footnotes (1)

Key Figures

Open-market purchase: 1,843 shares Purchase price: $2.97 per share Direct holdings after: 5,492 shares +2 more

5 metrics

Open-market purchase 1,843 shares Common Stock bought by CEO George K. Ng

Purchase price $2.97 per share Price paid for 1,843 Processa common shares

Direct holdings after 5,492 shares Common Stock directly owned by CEO after transaction

Indirect IRRA holdings 3,488 shares Indirect ownership via "George Ng IRRA FOB George Ng"

Indirect trust holdings 800 shares Indirect ownership via "Ng Cha Family Trust"

Key Terms

open-market purchase, Common Stock, indirect holdings, Form 4, +1 more

5 terms

open-market purchase financial

"He purchased 1,843 shares of common stock at $2.97 per share"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"He purchased 1,843 shares of common stock at $2.97 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

indirect holdings financial

"The filing also lists indirect holdings of 3,488 shares"

Form 4 regulatory

"The filing also lists indirect holdings of 3,488 shares"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

beneficial ownership financial

"showing both personal and related-entity ownership of Processa common stock"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		P		1,843	A	$2.97	5,492	D
Common Stock								3,488	I	George Ng IRRA FOB George Ng
Common Stock								800	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Processa Pharmaceuticals (PCSA) CEO George Ng do in this insider trade?

Processa CEO George K. Ng bought 1,843 shares of common stock in an open-market transaction. He paid $2.97 per share, increasing his directly owned stake to 5,492 shares. The filing also discloses additional indirect holdings through related entities.

How many Processa Pharmaceuticals shares does the CEO now hold directly?

After the reported transaction, CEO George K. Ng directly owns 5,492 Processa common shares. This reflects his 1,843-share open-market purchase at $2.97 per share, added to his prior direct holdings, as disclosed in the insider ownership table.

At what price did the Processa Pharmaceuticals CEO buy his new PCSA shares?

George K. Ng bought 1,843 Processa common shares at $2.97 per share. This open-market purchase price represents the per-share consideration he paid for this specific transaction, as reported in the insider trading disclosure for the common stock.

Does the Processa Pharmaceuticals CEO hold any indirect PCSA share ownership?

Yes. The disclosure shows 3,488 shares held indirectly under "George Ng IRRA FOB George Ng" and 800 shares held indirectly through the "Ng Cha Family Trust." These positions are reported as indirect ownership separate from his 5,492 directly held shares.

What type of insider transaction was reported for Processa Pharmaceuticals (PCSA)?

The transaction is an open-market purchase of common stock by CEO George K. Ng. It is classified with code P, indicating a purchase, and involves 1,843 shares at $2.97 each, increasing his direct ownership position in the company.

Are there any derivative securities involved in this Processa Pharmaceuticals insider filing?

No derivative transactions are listed in this disclosure. The filing shows only common stock positions, including the CEO’s open-market purchase of 1,843 shares and his direct and indirect common share holdings, with the derivative securities section reported as empty.